Edwin J. Ostrin, MD, PhD
Associate Professor of Pulmonary Medicine & Director of Oncopulmonology, NYU Langone Health
Physician-scientist studying the early biology of lung cancer and developing blood-based biomarkers to catch the disease sooner — from bench discovery to clinical validation.
The Ostrin Lab works at the intersection of lung cancer biology and clinical translation. Our research spans basic science into protein processing and metabolomic alterations during lung carcinogenesis, and translational and clinical studies of blood-based biomarkers for early lung cancer detection. Dr. Ostrin practices as a pulmonary/critical care physician with a clinical focus on the early diagnosis of cancer, and works closely with oncology and interventional teams to speed diagnosis and staging for patients with concerning imaging findings.
Research Focus
Blood-Based Biomarker Panels
Development and validation of a four-protein biomarker panel for lung cancer risk assessment and a ten-protein panel for multi-cancer risk assessment, moving toward clinical availability.
Indeterminate Pulmonary Nodules
Using protein biomarkers to help classify indeterminate pulmonary nodules found on imaging and guide clinical decision-making, reducing unnecessary procedures.
Mechanisms of Lung Carcinogenesis
Basic science investigating protein processing, the kynurenine pathway, and metabolomic reprogramming that drive tumor immunosuppression during lung cancer development.
Biomarker-Directed Screening
Collaborating on prospective trials and cohort studies (PLCO, NLST, LEAP) that pair biomarkers with lung cancer screening to improve early detection and reduce mortality.
Recent Highlights
- 2026 — The LEAP Study, a multicenter biospecimen and imaging resource for lung cancer screening, published in Cancer Epidemiology, Biomarkers & Prevention.
- 2025 — Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort (medRxiv).
- 2023 — Received the American Thoracic Society Thoracic Oncology Early Career Achievement Award.
- 2023 — Published mortality-benefit analysis of the four-protein biomarker panel using the PLCO cohort in the Journal of Clinical Oncology.